These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32173499)

  • 1. In vitro - In vivo correlation in the development of oral drug formulation: A screenshot of the last two decades.
    Davanço MG; Campos DR; Carvalho PO
    Int J Pharm; 2020 Apr; 580():119210. PubMed ID: 32173499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
    Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
    AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study.
    Wang J; Chen J; Wang L; Yang D; Shao R; Lou H; Ruan Z; Jiang B
    Clin Transl Sci; 2023 Jan; 16(1):85-91. PubMed ID: 36178248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
    Metry M; Polli JE
    AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?
    Shen J; Burgess DJ
    J Control Release; 2015 Dec; 219():644-651. PubMed ID: 26419305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
    Bredael GM; Bowers N; Boulineau F; Hahn D
    J Pharm Sci; 2014 Jul; 103(7):2125-2130. PubMed ID: 24890761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Gradually Expanding Scope for Biowaivers of Oral Products: An Overview.
    Saluja V; Singh A; Algradi AM
    Curr Pharm Des; 2016; 22(42):6434-6443. PubMed ID: 27396596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIP Guidelines for Dissolution Testing of Solid Oral Products.
    Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
    J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.
    Costello C; Rossenu S; Vermeulen A; Cleton A; Dunne A
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):519-39. PubMed ID: 21735135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based in vitro - in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron.
    Takahashi Y; Kambayashi A
    Eur J Pharm Biopharm; 2024 Nov; 204():114479. PubMed ID: 39233190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro/in vivo correlations in transdermal product development.
    Ghosh P; Milewski M; Paudel K
    Ther Deliv; 2015; 6(9):1117-24. PubMed ID: 26419538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.